首页> 外文期刊>Biochemical Pharmacology >Development of resistance to photodynamic therapy (PDT) in human breast cancer cells is photosensitizer-dependent: Possible mechanisms and approaches for overcoming PDT-resistance
【24h】

Development of resistance to photodynamic therapy (PDT) in human breast cancer cells is photosensitizer-dependent: Possible mechanisms and approaches for overcoming PDT-resistance

机译:人乳腺癌细胞中对光动力治疗(PDT)的抗性的发展是依赖的光敏剂:克服PDT抗性的可能机理和方法

获取原文
获取原文并翻译 | 示例
       

摘要

Graphical abstract Display Omitted Abstract Here we report on the induction of resistance to photodynamic therapy (PDT) in the ABCG2-high human breast cancer cell line MA11 after repetitive PDT, using either Pheophorbide A (PhA) or di-sulphonated meso -tetraphenylchlorin (TPCS 2a ) as photosensitizer. Resistance to PhA-PDT was associated with enhanced expression of the efflux pump ABCG2. TPCS 2a -PDT-resistance was neither found to correspond with lower TPCS 2a -accumulation nor reduced generation of reactive oxygen species (ROS). Cross-resistance to chemotherapy (doxorubicin) or radiotherapy was not observed. TPCS 2a -PDT-resistant cells acquired a higher proliferation capacity and an enhanced expression of EGFR and ERK1/2. p38 MAPK was found to be a death-signalling pathway in the MA11 cells post TPCS 2a -PDT, contrasting the MA11/TR cells in which PDT generated a sustained phosphorylation of p38 that had lost its death-mediated signalling, and an abrogated activation of its downstream effector MAPKAPK2. No difference in apoptosis, necrosis or autophagy responses was found between the treated cell lines. Development of TPCS 2a -PDT resistance in the MDA-MB-231 cell line was also established, however, p38 MAPK did not play a role in the PDT-resistance. MCF-7 cells did not develop TPCS 2a -PDT-resistance. Photochemical internalisation (PCI) of 1 pM of EGF-saporin induced equal strong cytotoxicity in both MA11 and MA11/TR cells. In conclusion, loss of p38 MAPK-inducing death signalling is the main mechanism of resistance to TPCS 2a -PDT in the MA11/TR cell line. This work provides mechanistic knowledge of intrinsic and acquired PDT-resistance which is dependent on choice of photosensitizer, and suggests PCI as a rational therapeutic intervention for the elimination of PDT-resistant cells. ]]>
机译:图形摘要显示摘要摘要在此摘要我们在重复PDT之后报告了ABCG2高人乳腺癌细胞系MA11中的抗性对光动力治疗(PDT),使用野吩硼吡硼吡酰α或二磺化的甲磺酰氯(TPC 2a)作为光敏剂。对PHA-PDT的抗性与Efflux泵ABCG2的增强表达相关。 TPCS 2A -PDT抗性既不发现与较低的TPC 2A-CACCUMUTULAULE也不降低反应性氧(ROS)。未观察到对化疗(多柔比星)或放射疗法的交叉抗性。 TPC 2A -PDT抗性细胞获得了更高的增殖能力和EGFR和ERK1 / 2的增强表达。发现P38 MAPK是TPCS 2A -PDT的MA11细胞中的死亡信令途径,对比其PDT产生的MA11 / TR细胞造影了P38的持续磷酸化,丧失了其死亡介导的信号传导,以及废除活化的活化它的下游效应器Mapkapk2。在处理过的细胞系之间发现细胞凋亡,坏死或自噬反应没有差异。在MDA-MB-231细胞系中的TPC 2A -PDT抗性的研制也建立,然而,P38 MAPK在PDT抵抗力中没有发挥作用。 MCF-7细胞没有产生TPC 2A -PDT抗性。在MA11和MA11 / TR细胞中,1PM的1PM诱导eGF-Saporin的PCI的光化学内化(PCI)。总之,P38 MAPK诱导死亡信令的丧失是MA11 / TR细胞系中TPC 2A-PDT的抗性的主要机理。这项工作提供了内在和获得的PDT抗性的机械知识,这取决于光敏剂的选择,并表明PCI作为消除PDT抗性细胞的合理治疗干预。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号